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PURPOSE: Good performance status is widely known as a superior prognostic predictor. However, some patients
have large survival differences despite having good performance status that are influenced by certain prognostic
factors. The purpose of this study was to explore baseline host- or tumor-related factors and to establish a
prognostic model for metastatic or recurrent gastric cancer patients with good performance status who received
first-line chemotherapy. METHODS: A total of 310 metastatic or recurrent gastric cancer patients with good
performance status who received first-line chemotherapy were enrolled. Prognostic significance was determined
using multivariate Cox regression analysis. Incorporating all pretreatment indicators, a prognostic model was
established. Overall survival outcomes were compared with different risk groups using the Kaplan-Meier method
and log-rank test. RESULTS: In multivariate analysis, no previous gastrectomy [hazard ratio (HR) = 1.42; 95%
confidence interval (CI) = 1.08-1.85], number of distant metastatic sites (HR = 1.47; 95% CI = 1.11-1.96), bone
metastasis (HR = 2.20; 95% CI = 1.16–4.18), liver metastasis (HR = 1.77; 95% CI = 1.31-2.39), and an elevated
neutrophil lymphocyte ratio (HR = 1.37; 95% CI = 1.04-1.79) were independent prognostic factors of overall
survival. Patients were categorized into three risk groups according to their risk scores. Median survival times for
the low-risk (0 point), intermediate-risk (1-3 points), and high-risk (≥4 points) groups were 19.7, 10.7 and 5.1
months, respectively (P b .001). CONCLUSIONS: A prognostic model was developed that could facilitate risk
stratification for metastatic or recurrent gastric cancer patients with good performance status who received first-
line chemotherapy to help clinicians choose an applicable treatment based on the estimated prognosis.
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Gastric cancer is the second most common cause of cancer-related
death in the world [1]. In China, this disease claimed approximately
297,496 lives in 2011 [2]. Although the only potential curative
treatment for gastric cancer is surgery, most gastric patients are usually
unable to receive curative surgical resection because of regional
advanced or distant metastatic disease at the time of diagnosis.
Palliative chemotherapy is still a major treatment in metastatic or
recurrent gastric cancer [3,4].
However, metastatic or recurrent gastric cancer patients who
receive palliative chemotherapy have varying survival outcomes. To
date, several studies have reported on prognostic indicators associated
with survival including host- and tumor-related factors. Some
prognostic models incorporating these prognostic factors have beendeveloped. This kind of prognostic tool can be simply used to help
oncologists guide treatment plans and improve prognostic accuracy
[5]. Lee et al. developed the first prognostic model for metastatic
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other prognostic models were gradually reported that focused on
patients treated with different specific first-line chemotherapeutic
regimens, such as cisplatin based, S-1 plus cisplatin, and docetaxel and
cisplatin plus fluorouracil [7–9].
Although several prognostic models have been reported, some issues
still need to be resolved. For example, patients analyzed in previous
models were too indiscriminate, including those patients with esophageal
cancer or squamous cell carcionomas [10]. More importantly, the patient
group in these prognostic models included those that had not only good
performance status (PS) but also poor PS.
Eastern Cooperative Oncology Group (ECOG) PS is an important
parameter which is widely used to assess responses to chemotherapy and
survival [11]. A good PS (0-1) has always been considered to have a better
beneficial prognostic impact than a poor PS (2-3) [6,12,13]. However,
some patients have a poor prognosis despite having a good PS. In a study
analyzing 148 cancer patients with a good PS, the report showed that
patients had a wide range of overall survival (OS) (29-2421 days) even
though they had a PS = 0 [14]. One potential explanation is that there are
several variables influencing survival, for example, histopathological
factors, biological behavior of the malignancy, and others. Even if it is the
same host-related factor, it could have different tumor-related effects.
Therefore, prognostic factors are probably different between good and
poor PS patient populations. Meanwhile, some subgroup analyses of
clinical trials showed that patients with a good PS belonged to mixed
groups who did not show good survival outcomes. The S-1 plus cisplatin
versus S-1 in random control trial in the treatment for stomach cancer and
S-1 alone versus S-1 and docetaxel combination in random control trial in
the treatment for stomach cancer studies found that the good PS group
did not show a statistically significant survival benefit from designated
chemotherapy regimens [15,16]. In other words, even though some
patients had the same good PS, appropriate treatments for both good and
poor PS patients should be tailored. Nevertheless, few studies have
analyzed prognostic factors among cancer patients with a good PS
[14,17]. To optimize treatment for this subset of patients, it will be
necessary to identify prognostic factors that can stratify patients within
this group.
To our knowledge, no prognostic model for metastatic gastric
cancer patients with a good PS is available. The objective of this study
was to explore baseline host- or tumor-related factors that may be
associated with survival and establish a prognostic model for
metastatic or recurrent gastric cancer patients with a good PS who
received first-line chemotherapy.Patients and methods
Patients
Between April 2007 and December 2013, 371 patients received
first-line palliative chemotherapy for metastatic or recurrent gastric cancer
at the First Hospital of ChinaMedical University. The criteria for patient
inclusion consisted of the following: 1) age ≥18 years, 2) histologically
confirmed diagnosis of gastric cancer, 3) presence of evaluable disease or
measurable lesions, 4) received at least one cycle of chemotherapy, 5) good
PS (0-1), and 6) availability of clinicopathological data at the start of
chemotherapy. Patients with esophageal cancer, squamous cell carcino-
mas, or gastroesophageal junction tumors were excluded from the
analysis. Of the 371 patients screened, 310 patients conformed with the
inclusion criteria. All patients in the study signed informed consents.Treatment
The 5-fluorouracil (5-FU)–based chemotherapy was as follows: 1)
oxaliplatin, capecitabine, or S-1 (n = 74); 2) oxaliplatin, leucovorin,
and 5-FU (modified FOLFOX) (n = 56); 3) capecitabine or S-1 (n =
45); 4) capecitabine or S-1 and cisplatin (n = 21); and 5) 5-FU and
cisplatin (n = 11).
The taxane-based chemotherapy was as follows: 1) docetaxel or
paclitaxel, and capecitabine or S-1 (n = 83); 2) docetaxel or paclitaxel,
cisplatin, and 5-fluorouracil (n = 10); 3) docetaxel and cisplatin (n =
1); and 4) docetaxel (n = 1).
Others included 1) an irinotecan-based regimen (n = 4); 2)
epirubicin, 5-FU, and cisplatin (n = 3); and 3) epirubicin, oxaliplatin,
and capecitabine (n = 1).
Statistical Analysis
OS was the primary end point of this study. OS was counted from
the time of metastasis to the time of death or the last follow-up visit.
Survival data was analyzed using the Kaplan-Meier method.
Comparison of survival curves were performed using log-rank
analysis. A multivariate prognostic model was performed using all
variables found to be significantly associated with OS at a P value ≤
.05 in the multivariate analysis. P values b .05 were considered
statistically significant, and all P values corresponded to two-sided
significance tests. All statistical analyses were performed using the
SPSS 17.0 software package (SPSS, Chicago, IL).
Variables included in the univariate analysis consisted of the
following: sex; age; PS; previous gastrectomy; tumor location; weight
loss; the number of distant metastatic sites; the presence of ascites;
metastasis to liver, bone, and lung at the start of chemotherapy; white
blood cell (WBC) count; absolute neutrophil count (ANC);
lymphocyte (LN) count; platelet count (PLT); neutrophil/lympho-
cyte ratio (NLR); platelet/lymphocyte ratio (PLR); hemoglobin; total
protein (TP); serum albumin (ALB); total bilirubin (TBIL); alanine
aminotransferase (ALT); and alkaline phosphatase (ALP). Laboratory
variables, recorded as continuous variables, were dichotomized based
on the median value of each variable.
Results
Patient Characteristics
From April 2007 to December 2013, 310 patients were included in
this study (Table 1). The median age was 58 years (range, 25-80
years).The percent of patients who had a PS = 0 at the time of receiving
first-line chemotherapy was 19.7 (n = 61). Eighty-one percent (251 of
310) of patients had more than one distant metastatic site. Nearly half of
the patients had previously received gastrectomies. There were 83 patients
(26.8%) who underwent palliative gastrectomies and 66 (21.3%) who
underwent radical gastrectomies. By the last follow-up date, 251 patients
had died. The median time of OS was 10.6 months [95% confidence
interval (CI) = 9.7-11.4] (Figure 1).
Univariate Analyses
We obtained complete information on all parameters on 296 of the
310 patients, and therefore, they were used in the prognostic analyses.
In univariate analysis, statistically significant factors that adversely
affected OS included no previous gastrectomy, bone and liver
metastasis, number of distant organ metastasis (≥2), the presence of
ascites, WBC count N6.4*109/l, ANC N3.8*109/l, PLT N230*109/
l, NLR N50th percentile, and PLR N50th percentile (Table 2).
Table 1. Clinical and Laboratory Characteristics of Patients
No. of Patients (N = 310)
Age (median age, range) 58.0 (25-80)
Sex
Male 213 (68.7%)
Female 99 (31.3%)
PS (ECOG)
0 61 (19.7%)
1 249 (80.3%)
Previous operation
No 161 (51.9%)
Palliative gastrectomy 83 (26.8%)
Radical gastrectomy 66 (21.3%)
Site of primary
Cardia/Fundus 42 (13.5%)
Body 76 (24.5%)
Pylorus/Antrum 136 (43.9%)
Repeat 45 (14.5%)
Unkown 11 (3.5%)
Grade
Well differentiated 22 (7.1%)
Moderately differentiated 60 (19.4%)
Poorly differentiated 130 (41.9%)
Signet ring 44 (14.2%)
Other/Unknown 54 (17.4%)
Weight loss
Yes 132 (42.6%)
No 170 (54.8%)
Number of distant metastatic site
0 59 (19.0%)
1 160 (51.6%)
2 69 (22.3%)
3 15 (4.8%)
4 7 (2.3%)
Metastasis
Liver 76 (24.5%)
Ascitic 38 (12.3%)
Lung 22 (7.1%)
Bone 11 (3.5%)
Complete blood count (median ± SD)
WBC, 109/l (N = 307) 6.4 ± 2.32
ANC, 109/l (N = 297) 3.8 ± 2.08
LN, 109/l (N = 296) 1.7 ± 0.64
Hemoglobin, g/l (N = 307) 114.0 ± 20.70
PLT, 109/l (N = 307) 230.0 ± 99.86
PLR (N = 298) 139.6 ± 81.09
NLR (N = 296) 2.2 ± 1.70
Blood chemistry (median ± SD)
TP, g/l (N = 296) 63.5 ± 6.75
ALB, g/l (N = 296) 38.2 ± 5.00
ALP, U/l (N = 301) 76.0 ± 97.74
ALT, U/l (N = 303) 15.0 ± 20.82
TBIL, μmol/l (N = 302) 8.4 ± 4.49
Figure 1.Overall survival of all patients. Themedian time of OSwas
10.6 months (95% CI = 9.7-11.4).
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Multivariate regression analysis included the variables that were
found to have prognostic significance in univariate analysis, as listed
above and in Table 2. The forward conditional Cox regression model
was used to delineate significant prognostic factors for survival. Five
factors were found to play an independent prognostic role: no
previous gastrectomy, number of distant metastatic sites, bone
metastasis, liver metastasis, and an elevated NLR (Table 3).
Then, a multivariate analysis prognostic model was constructed by
incorporating all five prognostic indicators. The risk scoring system
was distributed based on hazard ratios (HRs) from the final
multivariate analysis model, with 1 point for an HR b1.5 and 2
points for an HR N1.5. According to the risk scores, patients were
assigned to three risk categories: low risk (0 point), intermediate risk
(1-3 points), and high risk (≥4 points). Median survival times for
low-, intermediate-, and high-risk groups were 19.7, 10.7, and 5.1months, respectively. Survival curves according to the prognostic
model are shown in Figure 2. One-year survival rates for low-,
intermediate-, and high-risk groups were 63.4%,43.3%, and
17.2%.When compared with the low-risk group, the intermediate-r-
isk group had a 2.1-fold (HR = 2.07; 95% CI = 1.46-2.94) increased
risk of death, wheresa the high-risk group demonstrated a 3.7-fold
(HR = 3.66; 95% CI = 2.53-5.28) increased risk of death. There were
significant survival differences among the three risk groups (P b .001).
Discussion
Many variables potentially influence survival such as tumor grade,
tumor burden, nutritional status, and PS. PS is the most important
parameter for predicting survival in patients with metastatic gastric
cancer [10]. In a study analyzing 1455 metastatic gastric cancer
patients who received first-line chemotherapy, patients with a PS of 2
to 4 were found to be associated with a 1-year survival rate of 17.1%
compared with 39.2% for patients with a PS of 0 to 1 [6]. Evidently,
patients with a good PS were better able to tolerate the prescribed
dose and course of chemotherapy and usually had relatively good
survival outcomes. In our study, the median time of OS for all
patients with a good PS was 10.6 months, longer than predicted by
other prognostic models for metastatic gastric cancer patients (7.3-8.6
months) [6,7,10]. This highlights that having a good PS is a superior
prognostic predictor.
There was no previous prognostic model identified that could be
used to guide treatment for patients with a good PS. Our study was a
single-institution, retrospective study that analyzed data pooled from
patients with a good PS receiving first-line palliative chemotherapy for
metastatic gastric cancer. Five statistically significant independent
prognostic factors of poor survival (no previous gastrectomy, distant
organ metastasis ≥2, NLR N50th percentile, bone metastasis, and
liver metastasis) were identified. Using these factors, a prognostic
model to predict survival was developed that involved grouping
patients into three risk categories: low, intermediate, and high, with
significant survival differences.
It is recognized increasingly that tumors that occur or spread are
associated not only with tumor-related factors but also host
inflammatory factors [18]. These various factors have an important
impact in building a prognostic model. NLR was a useful host
Table 2. Univariate Analyses with Regard to OS in 296 Patients
Variable MST (Months) 1-Year Survival P Value HR (95% CI)
Sex
Male 10.8 49.5% .145 1.221
Female 10.1 38.0% (0.934-1.598)
Age
≤58 11.2 48.1% .832 1.028
N58 10.6 43.4% (0.797-1.327)
ECOG
0 12.9 50.9% .177 1.238
1 10.4 44.8% (0.908-1.686)
Previous gastrectomy
Yes 12.1 53.8% b .001 1.627
No 9.4 38.4% (1.258-2.104)
Weight loss
Yes 10.4 44.0% .134 0.818
No 11.2 47.4% (0.628-1.064)
Number of distant organ metastasis
0-1 11.9 51.7% b .001 1.728
≥2 8.0 31.8% (1.310-2.279)
Ascitic
No 11.2 47.7% .042 1.459
Yes 8.7 33.3% (1.014-2.099)
Liver metastasis
No 11.5 49.6% b .001 1.920
Yes 8.8 34.7% (1.430-2.576)
Lung metastasis
No 10.7 47.1% .631 1.117
Yes 8.7 31.8% (0.712-1.753)
Bone metastasis
No 10.7 46.5% .027 2.047
Yes 4.4 30.0% (1.084-3.864)
WBC
≤6.4*109/l 11.9 51.7% .033 1.318
N6.4*109/l 9.7 40.0% (1.022-1.700)
ANC
≤3.8*109/l 12.9 54.4% .001 1.555
N3.8*109/l 9.2 37.4% (1.205-2.007)
LN
≤1.7*109/l 9.1 40.3% .234 0.857
N1.7*109/l 11.8 51.7% (0.665-1.105)
Hemoglobin
≤114 g/l 10.7 45.7% .917 1.014
N114 g/l 10.8 46.2% (0.785-1.308)
PLT
≤230*109/l 11.9 51.3% .049 1.291
N230*109/l 9.8 40.3% (1.001-1.665)
PLR
≤50th percentile 12.6 53.7% .009 1.1.406
N50th percentile 9.5 38.1% (1.090-1.814)
NLR
≤50th percentile 13.6 57.4% b .001 1.623
N50th percentile 8.8 34.5% (1.256-2.096)
TP
≤63.5 g/l 10.4 43.2% .713 0.953
N63.5 g/l 11.1 48.6% (0.736-1.233)
ALB
≤38.2 g/l 10.1 41.8% .064 0.785
N38.2 g/l 11.3 50.0% (0.607-1.014)
ALP
≤76 U/l 11.1 48.6% .383 1.121
N76 U/l 10.4 42.4% (0.867-1.449)
ALT
≤15 U/l 10.7 44.3% .210 0.848
N15 U/l 10.8 47.8% (0.654-1.098)
TBIL
≤8.4 μmol/l 11.1 46.7% .329 0.880
N8.4 μmol/l 10.3 44.8% (0.680-1.138)
MST, median survival time.
Table 3. Multivariate Analysis with Regard to OS in 296 Patients
Factor HR 95% CI P Value
Liver metastasis 1.766 1.308-2.385 b .001
No previous gastrectomy 1.416 1.082-1.853 .011
Bone metastasis 2.198 1.156-4.181 .016
NLR N50th percentile 1.367 1.042-1.794 .024
Number of distant metastatic site ≥2 1.474 1.110-1.957 .007
Figure 2. Kaplan-Meier survival curves for survival probability
according to risk groups. The median survival differences between
low-, intermediate-, and high-risk groups (19.7, 10.7, and 5.1
months, respectively; P b .001) were statistically significant.
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revealed that an elevated NLR was an independent factor of OS in
multivariate analysis in patients with advanced gastric cancer [19–21].A current meta-analysis showed that OS was significantly worse in
patients with an elevated NLR value regardless of whether they had
resectable or metastatic gastric cancer [22].
In the present analysis, patients with an elevated NLR (NLR
N50th percentile) had a significantly poorer OS than those with a low
NLR. This is the first time that NLR has been incorporated in the
development of a prognostic model for metastatic gastric cancer. In
recent years, clinicians invested in resources and effort to develop
biomarkers for cancer patients. The NLR has distinct advantages
because it is easily obtained, convenient to monitor, and cost-effec-
tive. This parameter should be extensively used to analyze clinical
study results and in the design of future clinical trials. Other
host-response factors, such as PLR and hemoglobin and albumin
level, were also prognostically relevant in this study. Elevated PLR was
statistically significant in univariate analysis but not in multivariate
analysis. One possible reason why many studies have previously found
low hemoglobin and low albumin levels to be independent poor
prognostic factors for advanced gastric cancer was that, in these
studies, patients usually had a poor PS [6,9,23,24]. Although all
patients involved in our study had a good PS, these two factors were
not identified as prognostic in the present analysis.
Liver metastasis is usually found in gastric cancer because the
presence of liver metastasis is readily evident clinically or radiolog-
ically. For example, liver nodules are easily seen on ultrasound or
computed tomography scans. Although bone is not a common site of
metastasis in gastric cancer, previous studies have found that liver and
bone metastases were extremely poor prognostic factors in gastric
cancer patients [6–8]. In our study, we found that liver and bone
metastases were independent inferior prognostic factors in patients
with a good PS. In a study evaluating 1080 patients with
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with good and poor PS [6]. Liver and bone metastases were two
common poor prognostic factors for patients with good and poor PS.
The role of radical gastrectomy in operable gastric cancer patients is
relatively doubtless; however, the role of gastric resection in patients with
metastatic gastric cancer remains dismal. Some studies have demonstrated
that not having a prior gastrectomy was a statistically significant
prognostic factor of poor survival [8,25]. Reasons considered to explain
the benefit of palliative gastrectomy were as follows: First, palliative
gastrectomy could relieve potentially life-threatening complications such
as perforation, obstruction, or bleeding. Second, surgery could improve
outcomes by reducing tumor burden, increasing the quality of life and
responsiveness to adjuvant chemoradiotherapy. Third, surgical resection
for primary sites may reduce immunosuppressive cytokines produced by
the tumor [26–28]. A recent meta-analysis of 10 studies showed that
gastric resections were associated with a five-fold higher OS rate versus
nonsurgical treatment [29]. In our analysis, patients with previous
gastrectomy, either palliative or radical, had obvious survival superiority
when compared with those without previous gastrectomy, and its
prognostic significance was retained in multivariate analysis.
Previous prognostic models revealed that patients categorized in
the high-risk group had very poor survival outcomes (2.7-4.1
months) [6,7,10]. This subset of patients, who usually had a poor PS,
would be provided with the best supportive care. Nevertheless,
patients with a good PS in our models had a better predictive survival
rate. Notably, patients with high-risk factors had very poor survival,
approximately 5.1 months. This group of patients that had a good PS
was able to endure high-intensity treatment. Therefore, this subset of
patients may be candidates for more cytotoxic drug combination
chemotherapy regimens or for adding targeted agents rather than just
being provided with best supportive care. This strategy may be
crucial in developing new approaches or clinical trials for these
patients. That is the difference between our model and previous
prognostic models.
To the best of our knowledge, it is the first prognostic model for
this specific subset of patients.
Conclusions
Five prognostic factors were identified in patients receiving first-line
palliative chemotherapy for metastatic or recurrent gastric cancer. A
prognostic model was developed with distinct survival outcomes among
the different risk groups. Therefore, the constructed prognostic model
could be used to help oncologists identify patients that could possibly
benefit from current chemotherapeutic agents and aid them in selecting
an appropriate treatment based on the approximated prognosis.
Compliance with Ethical Standards
Ethical approval. All procedures performed in studies involving
human participants were in accordance with the ethical standards of the
First Hospital of China Medical University and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
Informed Consent. Written informed consent was obtained from
each participant before enrollment.
Acknowledgements
This work was supported by the National Science and Technology
Major Project (no. 2013ZX09303002) and Science and Technol-
ogy Plan Project of Liaoning Province (nos. 2011404013-1 and
2014225013).References
[1] Kamangar F, Dores GM, and AndersonWF (2006). Patterns of cancer incidence,
mortality, and prevalence across five continents: defining priorities to reduce
cancer disparities in different geographic regions of the world. J Clin Oncol
24(14), 2137–2150. http://dx.doi.org/10.1200/JCO.2005.05.2308.
[2] Chen W, Zheng R, Zeng H, Zhang S, and He J (2015). Annual report on status
of cancer in China, 2011. Chin J Cancer Res 27(1), 2–12. http:
//dx.doi.org/10.3978/j.issn.1000-9604.2015.01.06.
[3] Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, and Fleig WE (2006).
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis
based on aggregate data. J Clin Oncol 24(18), 2903–2909. http:
//dx.doi.org/10.1200/JCO.2005.05.0245.
[4] OrdituraM,GaliziaG, SforzaV,GambardellaV, Fabozzi A, LaterzaMM,Andreozzi F,
Ventriglia J, Savastano B, and Mabilia A, et al (2014). Treatment of gastric cancer.
World J Gastroenterol 20(7), 1635–1649. http://dx.doi.org/10.3748/wjg.v20.i7.1635.
[5] Lee CK, Hudson M, Stockler M, Coates AS, Ackland S, Gebski V, Lord S,
FriedlanderM, Boyle F, and Simes RJ (2011). A nomogram to predict survival time
in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer
Res Treat 129(2), 467–476. http://dx.doi.org/10.1007/s10549-011-1471-9.
[6] Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY,
and Sohn TS, et al (2007). Prognostic model to predict survival following
first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann
Oncol 18(5), 886–891. http://dx.doi.org/10.1093/annonc/mdl501.
[7] Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, and Kang YK (2008).
Prognostic factors for survival of patients with advanced gastric cancer treated
with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 61(2),
301–307. http://dx.doi.org/10.1007/s00280-007-0476-x.
[8] Koo DH, Ryu MH, Ryoo BY, Lee SS, Moon JH, Chang HM, Lee JL, Kim TW,
and Kang YK (2012). Three-week combination chemotherapy with S-1 and
cisplatin as first-line treatment in patients with advanced gastric cancer: a
retrospective study with 159 patients. Gastric Cancer 15(3), 305–312. http:
//dx.doi.org/10.1007/s10120-011-0117-2.
[9] Inal A, Kaplan MA, Kuukoner M, Urakci Z, Guven M, Nas N, Yunce M, and
Iikdogan A (2012). Prognostic factors in first-line chemotherapy treated
metastatic gastric cancer patients: a retrospective study. Asian Pac J Cancer Prev
13(8), 3869–3872.
[10] Chau I, Norman AR, Cunningham D, Waters JS, Oates J, and Ross PJ (2004).
Multivariate prognostic factor analysis in locally advanced and metastatic
esophago-gastric cancer–pooled analysis from three multicenter, randomized,
controlled trials using individual patient data. J Clin Oncol 22(12), 2395–2403.
http://dx.doi.org/10.1200/JCO.2004.08.154.
[11] Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, and
Carbone PP (1982). Toxicity and response criteria of the Eastern Cooperative
Oncology Group. Am J Clin Oncol 5(6), 649–655.
[12] Shitara K, Muro K, Matsuo K, Ura T, Takahari D, Yokota T, Sawaki A, Kawai H,
Ito S, and Munakata M, et al (2009). Chemotherapy for patients with advanced
gastric cancer with performance status 2. Gastrointest Cancer Res 3(6), 220–224.
[13] Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H,
YamaguchiK, andTakiuchiH, et al (2009). Fluorouracil versus combination of irinotecan
plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet
Oncol 10(11), 1063–1069. http://dx.doi.org/10.1016/S1470-2045(09)70259-1.
[14] Penel N, Vanseymortier M, Bonneterre ME, Clisant S, Dansin E, Vendel Y,
Beuscart R, and Bonneterre J (2008). Prognostic factors among cancer patients
with good performance status screened for phase I trials. Investig New Drugs
26(1), 53–58. http://dx.doi.org/10.1007/s10637-007-9088-x.
[15] Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K,
Nishizaki T, KobayashiO, andTakiyamaW, et al (2008). S-1 plus cisplatin versus S-1
alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Lancet Oncol 9(3), 215–221. http://dx.doi.org/10.1016/S1470-2045(08)70035-4.
[16] Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung
HC, Satoh T, and Cho JY, et al (2014). Addition of docetaxel to S-1 without
platinum prolongs survival of patients with advanced gastric cancer: a
randomized study (START). J Cancer Res Clin Oncol 140(2), 319–328. http:
//dx.doi.org/10.1007/s00432-013-1563-5.
[17] Moriwaki T, Ishige K, Araki M, Yoshida S, Nishi M, Sato M, Yamada T, Yamamoto
Y, Ozeki M, and Ishida H, et al (2014). Glasgow Prognostic Score predicts poor
prognosis among advanced biliary tract cancer patients with good performance status.
Med Oncol 31(11), 287. http://dx.doi.org/10.1007/s12032-014-0287-y.
Translational Oncology Vol. 9, No. 3, 2016 Gastric Cancer Patients w/ Good Performance Status Wang et al. 261[18] Mohri Y, Tanaka K,OhiM, Yokoe T,Miki C, andKusunokiM (2010). Prognostic
significance of host- and tumor-related factors in patients with gastric cancer.World J
Surg 34(2), 285–290. http://dx.doi.org/10.1007/s00268-009-0302-1.
[19] Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, and Fukushima
M (2007). The baseline ratio of neutrophils to lymphocytes is associated with
patient prognosis in advanced gastric cancer. Oncology 73(3-4), 215–220. http:
//dx.doi.org/10.1159/000127412.
[20] Qiu MZ,Wei XL, Zhang DS, Jin Y, Zhou YX, Wang DS, Ren C, Bai L, Luo HY,
and Wang ZQ, et al (2014). Efficacy and safety of capecitabine as maintenance
treatment after first-line chemotherapy using oxaliplatin and capecitabine in
advanced gastric adenocarcinoma patients: a prospective observation. Tumour
Biol 35(5), 4369–4375. http://dx.doi.org/10.1007/s13277-013-1574-5.
[21] Mohri Y, Tanaka K, Ohi M, Saigusa S, Yasuda H, Toiyama Y, Araki T, Inoue Y,
and Kusunoki M (2014). Identification of prognostic factors and surgical
indications for metastatic gastric cancer. BMC Cancer 14, 409. http:
//dx.doi.org/10.1186/1471-2407-14-409.
[22] Zhang X, Zhang W, and Feng LJ (2014). Prognostic significance of neutrophil
lymphocyte ratio in patients with gastric cancer: a meta-analysis. PLoS One
9(11)e111906. http://dx.doi.org/10.1371/journal.pone.0111906.
[23] Koo DH, Ryoo BY, Kim HJ, Ryu MH, Lee SS, Moon JH, Chang HM, Lee JL,
Kim TW, and Kang YK (2011). A prognostic model in patients who receive
chemotherapy for metastatic or recurrent gastric cancer: validation andcomparison with previous models. Cancer Chemother Pharmacol 68(4),
913–921. http://dx.doi.org/10.1007/s00280-011-1561-8.
[24] Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov
MN, Yakovleva ES, Garin AM, and Tjulandin SA (2010). A
prognostic model in patients treated for metastatic gastric cancer with
second-line chemotherapy. Ann Oncol 21(9), 1779–1785. http:
//dx.doi.org/10.1093/annonc/mdq032.
[25] Lee SS, Lee JL, RyuMH, Chang HM, Kim TW, Kang HJ, KimWK, Lee JS, and
Kang YK (2007). Combination chemotherapy with capecitabine (X) and
Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223
patients with prognostic factor analysis. Jpn J Clin Oncol 37(1), 30–37. http:
//dx.doi.org/10.1093/jjco/hyl134.
[26] McCarter MD and Fong Y (2001). Role for surgical cytoreduction in
multimodality treatments for cancer. Ann Surg Oncol 8(1), 38–43.
[27] Saidi RF, ReMine SG, Dudrick PS, and Hanna NN (2006). Is there a role for
palliative gastrectomy in patients with stage IV gastric cancer?World J Surg 30(1),
21–27. http://dx.doi.org/10.1007/s00268-005-0129-3.
[28] Pollock RE and Roth JA (1989). Cancer-induced immunosuppression:
implications for therapy? Semin Surg Oncol 5(6), 414–419.
[29] Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, and Zoras O
(2014). Gastrectomy for stage IV gastric cancer. a systematic review and
meta-analysis. Anticancer Res 34(5), 2079–2085.
